Loading
A phase 1/2 trial of BGB-16673 in follicular lymphoma and hodgkin lymphoma, run by BeOne Medicines, now recruiting.
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies is a phase 1/2 interventional study registered as NCT05006716 by BeOne Medicines, with 645 participants planned, started 2021-09-13 and due to reach its primary completion in 2026-11. Interventions recorded: Tacabrutideg. Conditions listed: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Shares BGB-16673, BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation), Mantle cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types).
Shares BGB-16673, BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation).
Shares BGB-16673, BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation).
Shares BeOne Medicines (formerly BeiGene), PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares BeOne Medicines (formerly BeiGene), Mantle cell lymphoma.
Shares PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.